Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Brain Res ; 830(2): 314-9, 1999 Jun 05.
Article de Anglais | MEDLINE | ID: mdl-10366688

RÉSUMÉ

We have compared the effects of an i.p. pretreatment with L-DOPA (200 mg/kg) associated with benserazide (25 mg/kg) on neurotoxic effects of either 6-hydroxydopamine (6-OHDA) (50 microg, 10 microl per mouse) or 1-methyl-4-phenylpyridinium (MPP+) (17.5 microg, 10 microl per mouse). The striatal dopamine (DA) content, the vesicular monoamine transporter (VMAT2) density, as well as the hypothalamic norepinephrine (NE) content were measured 8 days after treatments. The L-DOPA-benserazide pretreatment worsened by 65% the 6-OHDA-induced depletion in striatal DA. On the contrary, it reduced by 42% the MPP+-induced depletion in striatal DA and by 54% the MPP+-induced decrease in VMAT2 density. It was noticed that the L-DOPA-benserazide pretreatment did not modify the marked decrease in hypothalamic NE content induced by 6-OHDA.


Sujet(s)
1-Méthyl-4-phényl-pyridinium/toxicité , Lévodopa/pharmacologie , Protéines de transport membranaire , Neuropeptides , Neurotoxines/toxicité , Oxidopamine/toxicité , Analyse de variance , Animaux , Transport biologique , Interactions médicamenteuses , Hypothalamus/effets des médicaments et des substances chimiques , Hypothalamus/métabolisme , Injections ventriculaires , Mâle , Glycoprotéines membranaires/métabolisme , Souris , Agents neuromédiateurs/métabolisme , Norépinéphrine/métabolisme , Transporteurs vésiculaires des amines biogènes , Transporteurs vésiculaires des monoamines
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE